Third International Mdm2 Workshop

第三届国际MDM2研讨会

• 批准号: 7000510
• 负责人: UTE Martha MOLL
• 金额: $ 1万
• 依托单位: STATE UNIVERSITY NEW YORK STONY BROOK
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-15 至 2006-09-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7000510
• 关键词: meeting /conference /symposium; travel; tumor suppressor proteins; ubiquitin

DESCRIPTION (provided by applicant): Specific Objective: To obtain partial funding for the 3rd International MDM2 Meeting to enable young US trainees (graduate students and post docs) and US speakers to attend the meeting. Scientific Description: The MDM2 protein is the principal negative regulator of the tumor suppressor protein p53. MDM2, a p53-specific E3 ubiquitin lipase, mediates p53 degradation via the 26S proteasome pathway, thus keeping p53 levels in unstressed cells very low. Stress-induced posttranslational modifications of p53 disrupt the p53-MDM2 complex, thereby rapidly stabilizing p53 levels during a stress response. Accordingly, small molecule inhibitors of the p53-MDM2 complex hold great promise for development of novel cancer therapies in tumors that retain wild type p53 (about 50%) and are being vigorously developed by academic laboratories as well as by some major pharmaceutical companies. Conversely, amplification of MDM2 expression and its homolog MDMX by various means is an oncogenic pathway that suppresses the p53 tumor suppressive action and is realized in many human tumors. Participants: About 25-30 scientists from the USA, Canada, Europe, UK, Israel and Asia will give talks to present their latest findings. Based on previous attendances, we anticipate that 150-180 international scientists will attend the Meeting. Goals: Two International MDM2 Meetings dedicated to this rapidly growing field have been held to date. The agenda for the 3rd MDM2 Meeting is to discuss the newest MDM2 research in the context of the broader fields of tumor genesis, p53 tumor suppression, cell cycle control and apoptosis, and early mammalian development. Another focus will be MDM2 as a rational drug target. In this regard, a few invited speakers will be from the pharmaceutical industry working on such drugs. Topics convered: Structure and Function of MDM2, Stress Signaling Upstream of MDM2: Regulation of MDM2 by Posttranslational Modifications, Regulation of MDM2 function by Protein-Protein interactions, MDM2 Family members, Animal Models and Clinical Associations, Mdm2 proteins as therapeutic targets, other p53 Ubiquitin lipases and p53 Deubiquitylase.

描述（由申请人提供）： 具体目标：为第三届国际 MDM2 会议获得部分资金，以使年轻的美国学员（研究生和博士后）和美国演讲者能够参加会议。 科学描述：MDM2 蛋白是肿瘤抑制蛋白 p53 的主要负调节因子。 MDM2 是一种 p53 特异性 E3 泛素脂肪酶，通过 26S 蛋白酶体途径介导 p53 降解，从而使未受应激的细胞中的 p53 水平保持在非常低的水平。 应激诱导的 p53 翻译后修饰会破坏 p53-MDM2 复合物，从而在应激反应期间快速稳定 p53 水平。 因此，p53-MDM2复合物的小分子抑制剂对于开发保留野生型p53（约50%）的肿瘤的新型癌症疗法具有广阔的前景，并且学术实验室和一些主要制药公司正在大力开发。 相反，通过各种方式扩增MDM2及其同源物MDMX是抑制p53肿瘤抑制作用的致癌途径，并在许多人类肿瘤中实现。 参与者：来自美国、加拿大、欧洲、英国、以色列和亚洲的约 25-30 名科学家将发表演讲，展示他们的最新发现。 根据以往的出席情况，我们预计将有 150-180 名国际科学家参加会议。 目标：迄今为止，已经举办了两次专门针对这一快速发展领域的国际 MDM2 会议。第三次 MDM2 会议的议程是在肿瘤发生、p53 肿瘤抑制、细胞周期控制和细胞凋亡以及早期哺乳动物发育等更广泛领域讨论最新的 MDM2 研究。另一个焦点是 MDM2 作为合理的药物靶点。 在这方面，一些受邀演讲者将来自从事此类药物研究的制药行业。 讨论主题：MDM2 的结构和功能、MDM2 上游的应激信号：翻译后修饰对 MDM2 的调节、蛋白质-蛋白质相互作用对 MDM2 功能的调节、MDM2 家族成员、动物模型和临床关联、作为治疗靶点的 Mdm2 蛋白、其他 p53 泛素脂肪酶和 p53 去泛素化酶。